A detailed history of Group One Trading, L.P. transactions in Immunovant, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 59,007 shares of IMVT stock, worth $1.62 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
59,007
Previous 31,908 84.93%
Holding current value
$1.62 Million
Previous $1.03 Million 51.17%
% of portfolio
0.05%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $680,184 - $856,599
27,099 Added 84.93%
59,007 $1.56 Million
Q1 2024

May 10, 2024

SELL
$30.27 - $43.79 $3.2 Million - $4.62 Million
-105,599 Reduced 76.8%
31,908 $1.03 Million
Q4 2023

Feb 14, 2024

BUY
$31.31 - $44.19 $4.31 Million - $6.08 Million
137,507 New
137,507 $5.79 Million
Q2 2023

Aug 09, 2023

BUY
$14.2 - $23.75 $740,317 - $1.24 Million
52,135 Added 218.54%
75,991 $1.44 Million
Q1 2023

May 12, 2023

BUY
$15.27 - $19.72 $364,281 - $470,440
23,856 New
23,856 $370,000
Q3 2022

Nov 09, 2022

SELL
$3.93 - $6.37 $23,658 - $38,347
-6,020 Reduced 9.55%
57,027 $318,000
Q2 2022

Aug 11, 2022

BUY
$3.38 - $5.65 $20,067 - $33,544
5,937 Added 10.4%
63,047 $246,000
Q1 2022

May 12, 2022

SELL
$5.06 - $8.77 $137,551 - $238,403
-27,184 Reduced 32.25%
57,110 $315,000
Q4 2021

Feb 11, 2022

BUY
$7.33 - $9.32 $32,853 - $41,772
4,482 Added 5.62%
84,294 $718,000
Q3 2021

Nov 12, 2021

BUY
$7.01 - $11.37 $340,293 - $551,945
48,544 Added 155.25%
79,812 $694,000
Q2 2021

Aug 10, 2021

BUY
$9.4 - $16.85 $203,434 - $364,667
21,642 Added 224.83%
31,268 $331,000
Q1 2021

May 12, 2021

BUY
$13.08 - $49.6 $125,908 - $477,449
9,626 New
9,626 $154,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.